Trevi Therapeutics

TRVI64

High Growth

$3.50arrow_drop_up2.63%$0.09

High Growth

Penny Stock

TRVI64

$3.50

arrow_drop_up2.63%$0.09

High Growth

Penny Stock

Performance History

There's no data available for key stats

There's no data available for ratios/profitability stats

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Trevi Therapeutics (TRVI)

Trevi Therapeutics Inc (TRVI) is a biopharmaceutical company focused on developing therapies for patients with rare neurological disorders. The company's lead product candidate, nalbuphine ER, is being evaluated as a treatment for chronic pruritus, a debilitating condition characterized by intense itching. Nalbuphine ER is an extended-release formulation of nalbuphine, a well-known opioid that has demonstrated analgesic and itch-suppressing effects in preclinical and clinical studies.

Trevi Therapeutics Inc recently announced positive results from its Phase 2b/3 clinical trial evaluating nalbuphine ER in patients with prurigo nodularis, a severe form of chronic pruritus. The study met its primary endpoint, demonstrating a statistically significant reduction in itch severity compared to placebo. Secondary endpoints, including improvement in quality of life and reduction in prurigo nodules, were also achieved. These promising results support the potential of nalbuphine ER as a new treatment option for patients suffering from chronic pruritus.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Ms. Jennifer L. Good
Headquarters: New Haven
Employees: 30
Exchange: NASDAQ

Keep an eye on Trevi Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Trevi Therapeutics 's (TRVI) price per share?

The current price per share for Trevi Therapeutics (TRVI) is $3.5. The stock has seen a price change of $0.09 recently, indicating a 2.64% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Trevi Therapeutics (TRVI)?

For Trevi Therapeutics (TRVI), the 52-week high is $4, which is 14.29% from the current price. The 52-week low is $0.97, the current price is 260.82% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Trevi Therapeutics (TRVI) a growth stock?

Trevi Therapeutics (TRVI) has shown an average price growth of 0.41% over the past three years. It has received a score of 65 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Trevi Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Trevi Therapeutics (TRVI) stock price performance year to date (YTD)?

As of the latest data, Trevi Therapeutics (TRVI) has a year-to-date price change of 169.23%. Over the past month, the stock has experienced a price change of 17.85%. Over the last three months, the change has been 32.58%. Over the past six months, the figure is 1.16%. Looking at a longer horizon, the five-year price change stands at -25.53%.

help

Is Trevi Therapeutics (TRVI) a profitable company?

Trevi Therapeutics (TRVI) has a net income of -$29.06M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$33.92M. Furthermore, the EBITDA is -$43.03M.

help

What is the market capitalization of Trevi Therapeutics (TRVI)?

Trevi Therapeutics (TRVI) has a market capitalization of $247.54M. The average daily trading volume is 370.55K, indicating the stock's liquidity and investor engagement.